Lyka Labs has been granted an Indian patent for its proprietary product, Pregabalin Gel 8%, with patent protection valid through 2043. This significant milestone reinforces the company’s focus on innovation and its leadership in developing topical drug delivery systems.
Pregabalin Gel 8%, a topical formulation designed for the effective management of diabetic neuropathic pain, received regulatory approval from the Central Drugs Standard Control Organization (CDSCO) in October 2024 for manufacturing and marketing in India. This gel formulation represents a first-of-its-kind innovation in India, offering localized delivery of pregabalin directly at the site of pain, potentially minimizing systemic exposure and related side effects commonly associated with oral formulations.
With this patent, the company strengthens its intellectual property portfolio and reaffirms its vision to be at the forefront of innovative pharmaceutical solutions.
Lyka Labs is engaged in the manufacture of pharmaceutical products. It also manufactures Veterinary products including injections, powders, creams and suspensions.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1851.90 |
| Dr. Reddys Lab | 1273.00 |
| Cipla | 1332.95 |
| Zydus Lifesciences | 933.90 |
| Lupin | 2245.05 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: